Added to YB: 2026-06-02
Pitch date: 2026-03-27
COPN.SW [bullish]
Cosmo N.V.
-33.36%
current return
Author Info
No bio for this author
Company Info
Cosmo N.V., a life sciences company, develops and manufactures pharmaceuticals and contracts for gastroenterology, dermatology, and health tech in Ireland and internationally.
Market Cap
CHF 1.0B
Pitch Price
CHF 77.88
Price Target
N/A
Dividend
3.60%
EV/EBITDA
416.64
P/E
-151.39
EV/Sales
7.96
Sector
Pharmaceuticals
Category
growth
Cosmo N.V. - $COPN.SW
COPN.SW: Cosmo could launch Breezula in 2028, first FDA-approved MPHL drug in 30yrs—finasteride-like efficacy, no sexual side effects. P3 headline data positive; full readout/NDA pending. At 10% share (5m patients, $100/mo), ~$1.8bn rev to COPN, $1.2bn NI vs $1.775bn mkt cap. Multi-bagger potential. Risks: data flop/delay, FDA timeline, weak partner.
Read full article (6 min)